


CANADIAN NEUROLOGICAL SCIENCES FEDERATION

NEURO NEWS

cnsf.org



WORKING TOGETHER



ANNUAL EDITION 2021

Message from the CNSF President

Dear all-

I looked up Covid19 total mortality in Canada today (October 22) and the crude (unadjusted) mortality rate is about 74 per 100,000 population. This does not include indirect deaths that have occurred due to delays or changes in care and by some estimates, the total (direct and indirect) mortality may be double the crude rate. By comparison, the approximate crude (unadjusted) mortality rate due to stroke is 25 per 100,000 population. As a respiratory virus, the direct neurological impact of Covid19 has been small, but we have seen multiple indirect effects from delays in neurosurgical care due to cancellation of ORs, to changes in stroke admissions and the impending concerns about so-called 'long-Covid' syndrome.

For the CNSF, we have now had to cancel the in-person Congress in two sequential years. The Scientific Program Committee, chaired with much thanks by Joe Megyesi and the CNSF Executive/Board considered moving to an on-line format and ultimately decided against this option for a variety of reasons. Despite this, we have successfully moved to on-line learning with serial CME offerings by webinar. Our sponsors have stuck with us and we will continue that again this year. A key learning is that continued engagement of members throughout the year with learning series on-line has been well received and is something we should continue into the future. We are still planning for a Montreal in-person Congress in 2022.

We welcomed the Canadian Stroke Consortium as an official 6th society into the Federation. This strengthens the CNSF and I hope, continues to embolden the philosophy that we are stronger together as a clinical neuroscience community in Canada. I hope that as a larger group we can pursue initiatives in advocacy for our patients, continue our biggest role in education, and explore issues of interest to physicians in the business of medicine. There are initiatives afoot to further engage with neuroscience nurses (CANN), electrophysiology (CAET) and others involved in clinical neuroscience.

We are planning to host the WFN in Montreal in 2023 and work will start in earnest in the upcoming year with the CNS taking the lead together with the MNI.

I would like to thank all of the CNSF Societies and the CNSF Executive and Board for their engagement and accountability in moving the CNSF forward. The SPC has done yeoman's work, and struggled with multiple difficult decisions. The CJNS, led by Editor-in-Chief, Dr. Robert Chen, is doing well with rising impact factor and with engagement from new member societies in the CNSF. The future of the CJNS Journal looks bright. Finally, thanks to the CNSF Secretariat lead by Dan Morin who have shown tremendous adaptability preserving the success of the CNSF.

Onwards!



Michael D Hill
CNSF President



Like us on Facebook:
facebook.com/CNSFNeuroLinks



Follow us on Twitter:
twitter.com/CNSFNeuroLinks

CNSF Vision

The improved wellbeing of children and adults with diseases, disorders and injuries of the nervous system and the prevention of these conditions.

CNSF Mission

To support the neuroscience professions in Canada, and particularly those members of the CNSF Societies, through education, advocacy, membership services and research promotion.

Notes about the Mission:

- **Education** includes the annual CNSF Congress, The Canadian Journal of Neurological Sciences (CJNS), and all other continuing professional development (CPD) activities.
- **Membership Services** include services delivered to the constituent Societies of the CNSF and their individual members, the research to identify member needs, and other related activities.
- **Advocacy** includes activities such as building public awareness about diseases, disorders and injuries of the nervous system, and advocacy for improved public policy and increased medical research. Such advocacy may be direct or in collaboration with other organizations.



CNSF Strategic Priorities

To ensure the achievement of its Vision and Mission, the CNSF has **three strategic priorities**: Continuing Professional Development, Membership Value, and Advocacy. The **goals** of these three priorities are noted below. Responsibility for expanding and putting these elements into operation has been assigned to one or more of the CNSF constituent societies, committees, or staff.

1. Continuing Professional Development:

The **goal** of this priority is to review, refine, improve and expand the overall CNSF CPD plan to meet the evolving needs of Society members while continuing to focus on the CNSF's priorities, i.e. the Congress and the Journal.

2. Membership Value:

The **goal** of this priority is to review, refine, improve and expand the overall CNSF CPD plan to meet the evolving needs of Society members while continuing to focus on the CNSF's priorities, i.e. the Congress and the Journal.

3. Advocacy:

The **goal** is to increase awareness of the impact and burden of diseases, disorders and injuries of the nervous system in Canada on affected individuals, their families, and communities, and the health-care system. The targets of this priority are the policy-makers at all levels of government, the general public and affiliated health care providers.

The CNSF Board is currently reviewing its Strategic Plan to insure that the Goals, Objectives and Strategies, as listed above, are current and relevant to meet the needs of the organization and its members

cnsf.org/about-cnsf



Look at you now.

You weren't born a physician. Years of hard work, dedication and focus have led you right here. With the combined expertise of MD Financial Management and Scotiabank Healthcare+ you have a full suite of specialized financial planning services for every stage of your career. You've come a long way. Take your finances further with a team of specialists focused on your financial health.

Get started at md.ca/gofurther



Committed
to physicians

MD Financial Management (MD Financial) provides financial products and services, the MD Family of Funds and investment counselling services through the MD Group of Companies. For a detailed list of the companies, visit md.ca. All banking and credit products and services available through the Scotiabank Healthcare+ Physician Banking Program are offered by The Bank of Nova Scotia (Scotiabank). Credit and lending products are subject to credit approval by Scotiabank. ®Registered trademark of The Bank of Nova Scotia, used under licence.

CNSF Foundations

- The CNSF's major priorities, as determined by the CNSF Board's Strategic Planning document are: Continuing Professional Development (through the Congress and Journal); Advocacy (in particular through our involvement with Neurological Health Charities Canada) and Membership retention and growth.
- The CNSF has four main sources of revenue: Membership dues, Congress registration fees, Journal subscription revenue and Industry sponsorship and Exhibitor revenues. All four are vital to our continued success and growth.
- It is very important that our Members renew their membership each year and we hope that each member can recruit others to join. The benefits of membership page is included in this Neuro|News and a Power Point presentation on "The CNSF and why you should join" is on our website.
- The CNSF has four staff; Marika, Donna and Dan have been with the CNSF for a total of 47 years. Nicole, who started in 2017 and who works part time, provides assistance to everyone. She is a most valued addition to the Secretariat.
- We 'contract' services to third parties such as Intertask Conferences for the Congress and Cambridge University Press for the Journal.



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION

FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA



CNSF Board of Directors 2021–2022



Michael Hill
CNSF President
CNS Member



Kesh Reddy
CNSF Past President
CNSS Member




Kristine Chapman
CNSF Vice-President
CSCN Member



Cecil Hahn
CNSF Vice-President
CACN Member



Tejas Sankar
CNSF Vice-President
CNSS Member



Christian Stapf
CNSF Vice-President
CSC Member



Karel Terbrugge
CNSF Vice-President
CSNR Member



Michelle Demos
CACN President



Michael Esser
CACN Vice-President



Dhany Charest
CNSS President



John Wong
CNSS Vice-President



Steven Peters
CNS President



Alex Henri-Bhargava
CNS Vice-President



Juan Pablo Appendino
CSCN President



Steven Baker
CSCN Vice-President



Donatella Tampieri
CSNR President



Rob Sevick
CSNR Vice-President



Andrew Demchuk
CSC Chair



Ashfaq Shuaib
CSC Vice-Chair



Ian Fleetwood
CNSF At-Large



Aleksandra Mineyko
CNSF At-Large



Joseph Megyesi
CNSF SPC Chair
CNSS Member



Cian O'Kelly
CNSF PDC Chair
CNSS Member



Robert Chen
CJNS
Editor-In-Chief
CNS & CSCN Member



Jeanne Teitelbaum
CNSF Membership
Committee Chair
CNS Member



Draga Jichici
CNSF CPGC Chair
CNS Member



Dan Morin
CNSF
Chief Executive officer



**Michelle
Kameda-Smith**
CNSS



Sr. Resident Rep
Michael Rizzuto
CNSS
Jr. Resident Rep



Jeremiah Hadwen
CNS
Sr. Resident Rep



Shane Arsenaault
CNS
Sr. Resident Rep



Hayley Thornton
CNS
Jr. Resident Rep



Kirsten Sjonnesen
CACN
Sr. Resident Rep



Lindsey Logan
CACN
Jr. Resident Rep



Daniel Duggan
CSNR
Resident Rep



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA



LOOK FOR “RED-FLAG” SYMPTOMS

Hereditary ATTR (hATTR) amyloidosis

Hereditary ATTR amyloidosis is an inherited, rapidly progressive disease that causes sensory-motor polyneuropathy that may be accompanied by autonomic or cardiac symptoms, eventually robbing patients of function – and even their lives.¹⁻⁵

With increased research and development in hATTR amyloidosis, it is now more critical than ever to be aware of red-flag symptom clusters.^{1,5}

To learn more about hATTR amyloidosis, visit www.hattramyloidosis.ca

Alnylam is a biopharmaceutical company developing a potential new class of innovative medicines. We have a core focus on therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

To learn more about Alnylam, please visit www.alnylam.ca.


GI=gastrointestinal tract; TTR=transthyretin

References: 1. Conceição I, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. *J Peripher Nerv Syst* 2016;21:5-9. 2. Hanna M. Novel drugs targeting transthyretin amyloidosis. *Curr Heart Fail Rep* 2014;11:50-57. 3. Adams D, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology* 2015;85:675-82. 4. Damy T et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. *J Cardiovasc Transl Res* 2015;8(2):117-17. 5. Mohty D, et al. Cardiac amyloidosis: updates in diagnosis and management. *Arch Cardiovasc Dis* 2013;106(10):528-40.



Variable clinical presentation¹

Suspect hATTR amyloidosis if **progressive peripheral sensory-motor polyneuropathy** is observed with one or more of the following:¹



Adapted from
Conceição I, et al. 2016.

Message from the CNSF CEO

The Annual Edition Neuro|News is traditionally in printed form and distributed at our Congress. This year we are mailing it to the entire membership and we hope that you can review its contents to learn more about the CNSF and the 6 Societies of the Federation.

The past two years for the CNSF have been everything but normal or traditional. Cancelling two of our Congresses was very disappointing, but necessary, of course.

Most importantly, we hope that you and your families are healthy and safe, and remain so.

The CNSF and each of its' Societies are still functioning, not necessarily as normal, but functioning, nevertheless. We continue with AGM's and Board meetings, Membership renewals and more. Most importantly, we have started planning for our 2022 Congress in Montreal, June 26-29. A special thanks to our Congress Chairs and Speakers who have committed to carrying their 2021, and in some cases their 2020, Congress Program and courses to 2022. It promises to be an outstanding and current program to meet your educational needs.

At the time our 2020 and 2021 Congresses were cancelled, we had secured significant support from Pharma and Medical Equipment companies in the form of Lunch 'n Learns, advertising, booth purchases and more. Thanks to these 'supporters' we have transitioned from live Lunch 'n Learns to online Webinars that are being scheduled from mid-October


to early December 2021 and even into 2022. These webinars have essentially saved the past two years for us financially. We sincerely appreciate all of our sponsoring organizations who are listed in this edition of Neuro|News.

Our volunteer physicians make it all come together and contribute to our success. Members of the CNSF owe a debt of gratitude to their fellow members who take on these vital and sometimes onerous responsibilities. Our Board members, chairs and vice-chairs, and committee members are listed throughout this year's Neuro|News. Why not stop them and say thanks.

The Secretariat, manned so professionally by Marika, Donna and Nicole do wonderful work to keep the administrative aspects of the Societies, the CNSF and the CJNS Journal on track. They are vital to those aspects; and more. They, too, deserve a great deal of thanks.

On behalf of the Secretariat, our best wishes, and we hope to see you in person in Montreal.

Kindest Regards,



Dan Morin
Chief Executive Officer
Canadian Neurological Sciences
Federation

2021–2022 Society Boards of Directors and Committee Reps

The Canadian Neurological Sciences Federation (CNSF) is comprised of member Societies, representing different specialties of the Neurosciences.

Special thanks to these dedicated Board members that volunteer their time to contribute to the success of their individual Society as well as collective CNSF initiatives.




Canadian Neurological Society  Société canadienne de neurologie

Canadian Neurological Society (CNS)

CNS President.....	Steven Peters
CNS Vice President.....	Alex Henri-Bhargava
CNS Secretary Treasurer	Alice Schabas
CNS Past President	Jodie Burton
Rep from Manitoba	James Marriott
Rep from Newfoundland	Linda Magnusson
Rep from Saskatchewan	Ilija Poliakov
Reps from Ontario.....	Alex Jahangirvand, Reza Vosoughi
Rep from Quebec.....	Alby Richard
Rep from Alberta.....	Brian Buck
CNSF CEO	Dan Morin
Residents’ Reps	Jeremiah Hadwen, Shane Arseneault & Jr rep. Hayley Thornton
Reps on CNSF PDC Committee	Alex Henri-Bhargava, Shannon Venance, 3 Resident Reps.
Reps on CNSF SPC Committee	Gerald Pfeffer (Vice Chair), Draga Jichici, 3 Resident Reps.
Choosing Wisely Campaign	Philippe Couillard
CNS Rep on CNSF Executive Committee	Michael Hill



The Canadian Neurosurgical Society  Société canadienne de neurochirurgie

Canadian Neurosurgical Society (CNSS)

CNSS President	Dhany Charest
CNSS Vice President	John Wong
CNSS Secretary Treasurer	Gwynedd Pickett
CNSS Past President	Pat McDonald
Rep from British Columbia	Gary Goplen
Rep from Alberta	Vivek Mehta
Rep from Saskatchewan	Lissa Peeling
Rep from Manitoba	Colin Kazina
Rep from Ontario	Eric Massicotte
Rep from Quebec	Louis Crevier
Rep from Newfoundland & Labrador	Roger Avery
Rep from New Brunswick	Robert Adams
Rep from Nova Scotia	Sean Christie
CNSF CEO	Dan Morin
Residents’ Reps	Michelle Kameda-Smith & Jr rep. Michael Rizzuto
Reps on CNSF PDC Committee	Cian O’Kelly (Chair), 2 Resident Reps
Reps on CNSF SPC Committee	Joe Megyesi (chair), 2 Resident Reps
Choosing Wisely Campaign	Gwynedd Pickett
Canadian Concussion Collaborative	Michael Ellis
AANS	Pat McDonald, Dhany Charest
WFNS.....	Dhany Charest, Pat McDonald (alternate)
Royal College NS Specialty Committee.....	Cian O’Kelly
CNSS Rep on CNSF Executive Committee	Tejas Sankar



Canadian Society of Clinical Neurophysiologists (CSCN)

CSCN PresidentJuan Pablo Appendino
 CSCN Vice PresidentSteve Baker
 CSCN Secretary TreasurerChristine Stables
 CSCN Past PresidentFraser Moore
 Secretary EMG SectionDina Namiranian
 Chair of EMG SectionCecile Phan
 Chief Examiner EMGLawrence Robinson
 Chair of EEG Section and Chief Examiner EEG Marcus Ng
 Secretary EEG SectionMichelle-Lee Jones
 CNSF CEODan Morin
 Reps on CNSF PDC Committee Seyed Mirsattari
 Reps on CNSF SPC Committee Michelle Mezei, Kristen Ikeda
 CSCN Rep on CNSF Executive Committee Kristine Chapman



Canadian Association of Child Neurology (CACN)

CACN PresidentMichelle Demos
 CACN Vice-President Michael Esser
 CACN Secretary TreasurerSunita Venkateswaran
 CACN Past President Simon Levin
 Rep from Western CanadaAnita Datta
 Rep from Central CanadaSamantha Marin
 Rep from Eastern CanadaDavid Dufresne
 CNSF CEODan Morin
 Residents' Reps Kirsten Sjonnesen & Jr rep. Lindsey Logan
 Reps on CNSF PDC Committee Maryam Nouri, 2 Resident Reps
 Reps on CNSF SPC CommitteeHugh McMillan, Helly Goez,
 2 Resident Reps
 Rep on CACN Education CommitteeAleksandra Mineyko
 Rep on CPSPElizabeth Donner
 CACN Rep on CNSF Executive CommitteeCecil Hahn



Canadian Society of Neuroradiologists (CSNR)

CSNR President Donatella Tampieri
 CSNR Vice PresidentRob Sevick
 CSNR Secretary Treasurer Matthias Schmidt
 CSNR Past President Karel Terbrugge
 Rep from British ColumbiaJason Chew
 Rep from SaskatchewanTasha Ellchuk
 Rep from OntarioRichard Aviv
 Rep from OntarioWilliam Miller
 Rep from Nova ScotiaJai Shankar
 CNSF CEODan Morin
 Residents' Rep Daniel Duggan
 Reps on CNSF PDC CommitteeDavid Mikulis (Vice Chair)
 and Resident Rep.
 Reps on CNSF SPC CommitteeLaila Alshafai, Jai Shankar
 and Resident Rep.
 Social Media Task Force Fateme Salehi
 CSNR Rep on CNSF Executive Committee Karel Terbrugge



Canadian Stroke Consortium (CSC)

CSC ChairAndrew Demchuk
 CSC Vice ChairAshfaq Shuaib
 CSC Past ChairMike Sharma
 CSC Rep on CNSF Executive Committee Christian Stapf
 Brian Buck
 Leanne Casaubon
 Shelagh Coutts
 Dar Dowlatshahi
 Thalia Field
 Michael Hill
 Tom Jeerakathil
 Jennifer Mandzia
 Alex Thiel

OUR MISSION:

More moments like this.

At Amylyx, our progress is measured by the moments we can give back to those living with neurodegenerative diseases. As a pharmaceutical company, that might make us a little different. But that's what inspires us to question the obvious, go against the grain, and find new ways to slow the advancement of these diseases.

Visit us at [amylyx.com](https://www.amylyx.com) to learn more.



© Copyright 2021 Amylyx Pharmaceuticals, Inc. All Rights Reserved. AMX-2021-1636-08/2021

Where will we meet in 2022?

Join us in beautiful Montreal, Quebec
Sunday, June 26 – Wednesday, June 29, 2022
Queen Elizabeth II Hotel

Plan on attending and experiencing the luxury and convenience of this fabulous venue. The QEII is located in the heart of romantic and cosmopolitan Montreal, where French and English meet. Fairmont Queen Elizabeth offers guests outstanding comfort and attentive service. Ideally located above the VIA Rail Central Train Station, you will be minutes away from all of the excitement that Montreal has to offer: shopping, dining, festivals and the historical Old Montreal.



Photo: © Hanqian Jiang

Dr. Emgality[®]
(galcanezumab) injection

FOR
POWERFUL
MIGRAINE
PREVENTION

FOR
POWERFUL REDUCTION
IN THE FREQUENCY OF
EPISODIC CLUSTER
HEADACHE ATTACKS

THINK EMGALITY[®]



EMGALITY is indicated for the prevention of migraine in adults who have at least 4 migraine days per month.



EMGALITY is indicated for the reduction in the frequency of attacks throughout a cluster period in adults with episodic cluster headache with prior cluster headache periods lasting at least 6 weeks and who have had an inadequate response to, or tolerated poorly, or had contraindications to conventional preventive therapies established by Canadian practice guidelines.

Clinical Use:

For patients with episodic cluster headache, the treatment benefit should be assessed within 3 weeks after initiation of the treatment. In patients with no improvement within this time period, continuation of the treatment should be carefully considered based on individual patient basis and clinical judgement.

Emgality should be initiated by physicians experienced in the diagnosis and treatment of migraine or episodic cluster headache.

Geriatrics (≥65 years of age): The safety and efficacy of Emgality has not been studied in patients aged 65 or older.

Relevant Warnings and Precautions:

- Serious hypersensitivity including anaphylaxis. These reactions may occur within minutes, although some may occur up to one month after administration
- Patients with cardiovascular disease
- Patients with vascular disorders (episodic cluster headache indication)
- Pregnant and nursing women
- Pediatrics (<18 years of age)

For More Information:

Please consult the product monograph at <http://pi.lilly.com/ca/emgality-ca-pm.pdf> for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed here. The product monograph is also available by calling Eli Lilly Medical Information at 1-888-545-5972.

● **The FIRST AND ONLY CGRP binding antibody with indications in ALL 2 of the following authorized uses: Migraine prevention; Episodic cluster headache.***

The images depicted contain models and are being used for illustrative purposes only. | CGRP=calcitonin gene-related peptide | * Comparative clinical significance unknown.

Reference: 1. Emgality product monograph. Eli Lilly Canada Inc. September 17, 2020.

Emgality is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates. | © 2021 Eli Lilly and Company. All rights reserved.

PP-GZ-CA-0145A EN

MEMBER OF
INNOVATIVE MEDICINES CANADA



Lilly

Where will we meet in 2023?

Let's get back to the Rocky Mountains and Banff, Alberta

Sunday, June 4 – Wednesday, June 7, 2023
Banff Springs Hotel

Few hotels in the world rival the majesty, hospitality and grandeur of The Fairmont Banff Springs resort. Styled after a Scottish Baronial Castle, and located in the heart of Banff National Park, a UNESCO World Heritage Site, the Fairmont Banff Springs hotel, has been turning moments into memories for over 125 years. The opening of the hotel in 1888 marked the birthplace of tourism in the Canadian Rockies, and is now a National Historical Site of Canada.

The Fairmont Banff Springs provides unparalleled options and unique experiences to guests, from inclusive onsite getaways to days of adventure exploring the Canadian Rockies.



**Eli Lilly is a proud
sponsor of the 2021
CNSF Congress**

© 2021 Eli Lilly and Company.
All rights reserved.
PP-GZ-CA-0164A EN



Benefits of CNSF Membership

Our Member Societies

CNSF members belong to one, or more, of our Societies:



Membership in the Community of Canadian Clinical Neuroscientists

The community of clinical neurologists, neurosurgeons, pediatric neurologists, neurophysiologists and neuroradiologists is a robust and growing family that has made a long-standing, international, and ongoing contribution to clinical neuroscience. The community provides continuing medical education for its members, teaching for residents, students and clinical fellows. There is strong clinical and discovery-based research in Canada.

Networking in this group provides opportunity for training (e.g. fellowships), for collaboration across the country and for mutual learning.

Congress

Our Federation, assisted by the Professional Development and the Scientific Program Committees, hosts a Canadian Congress geared towards the Continuing Professional Development (CPD) learning needs of Neurologists, Neurosurgeons, Pediatric Neurologists, Neurophysiologists, Neuroradiologists and Neuroscientists.

Our Congress is an accredited learning activity; therefore, you earn Maintenance of Certification (MOC) credits.

Gather with your colleagues and friends from across the country.

Learn, Mentor, Share, Teach, Collaborate, Advocate.

Members attend the CNSF Congress at a generously discounted registration fee.

Annual Society Prizes

Members have the opportunity to win valuable society prizes by submitting an 'Abstract' to the Congress as well as an 'Expanded Abstract' to the society competitions.

There are multiple first place prizes available to Junior Members or an Active Member within two years of receiving their certificate. Each valued at approximately **\$2500**.

Winners have the privilege of presenting their work at the Grand Plenary, alongside our Distinguished Guest Lecturers, during the Congress. Prize winners' will be announced in the Neuro|News newsletter, in the Canadian Journal of Neurological Sciences and on the CNSF website.

\$500 second place prizes and additional subsidiary prizes may be awarded.

Canadian Journal of Neurological Sciences (CJNS)

The Canadian Journal of Neurological Sciences (CJNS) is the official publication of our member Societies. The Journal is an internationally recognized, peer reviewed medical journal, published through Cambridge University Press – Cambridge Core.

Members receive an online subscription with exclusive access to the most current year of the publication and 'Magazine View' of each issue.

CNSF Members submitting an article to the CJNS receive GOLD open access at half price.

Member Only Information

Members receive a bi-monthly CNSF Neuro|News electronic newsletter featuring:

- Society and Federation news
- Congress details and updates
- Job postings
- Advocacy items
- Messages from the CNSF and Society Presidents
- CJNS Journal Highlights
- Webinars and other CNSF CME Opportunities
- Continuing Professional Development (CPD) opportunities

Access to additional information on the CNSF website.

Our website contains the latest information for our National Specialty Societies and all that the Canadian Neurological Sciences Federation has to offer. Members receive the added benefit of 'member only' information such as CJNS journal access, past webinar recordings, quick access to Society driven initiatives, information and resource links.

Residents

PGY1 residents can apply for complimentary first-year membership, paid by their member Society. Membership dues for subsequent years of residency are only \$80/year.

Congress registration fees for resident members is only \$250. This registration fee includes access to all Congress courses/sessions, course notes, luncheons, breaks and the Residents Social.

CNSF Society Resident Representatives help organize a resident social event. This is a major networking event for trainees to connect with attending physicians from a wide variety of backgrounds and subspecialties.

The newest benefit for our Junior members is the CNSF prepOSCE neurology sessions, offering virtual practice OSCE sessions for those preparing for their Royal College exams.

Resident members receive all 'benefits' outlined in the sections above as well as any additional benefits provided by their individual Society, such as CNS Leaders in Neurology interviews for publication in the CJNS and the CACN Mentorship Program.

The CNS, CNSS, CACN and CSNR, all have resident representatives that sit on the CNSF Professional Development and Scientific Program Committees and attend the CNSF Board of Directors meetings, as well as their respective Society Board meetings.

Resident members are welcome to contact their society resident representative with any issues, concerns or ideas that they would like to see discussed.

Not a member of the CNSF?

- ▶ **Would you like to become a member of one of the CNSF National Specialty Societies?**
- ▶ **Would you like to take advantage of the Benefits of CNSF Membership?**

Download the appropriate society application form by choosing your society of interest or contact Donna Irvin, CNSF Member Services at: donna-irvin@cnsf.org / www.cnsf.org

Become a Member | CNSF

cnsf.org/about-cnsf/membership/become-a-member

Why you should join

cnsf.org/media/n3go5aas/the-cnsf-why-you-should-join_2021-10-06.pdf

Associate and Affiliate Societies of the CNSF

Associate Societies of the CNSF are professional societies that have similar goals to the CNSF. They are:

- Canadian Association of Neuroscience Nurses (CANN)
- Canadian Association of Electroneurophysiology Technologists Inc. (CAET)
- The Association of Electromyography Technologists of Canada (AETC)
- Canadian Association for Neuroscience (CAN)
- Canadian Association of Physical Medicine & Rehabilitation (CAPM&R)
- Canadian Apheresis Group (CAG)

Affiliate Societies work collaboratively with the CNSF whenever possible throughout the year. The CNSF values and appreciates these partnerships. They are:

- Canadian ALS Trials and Research Network
- The Canadian Brain Tumour Consortium
- The Canadian Headache Society
- The Canadian League Against Epilepsy
- The Canadian Movement Disorders Group
- The Canadian Network of MS Clinics
- The Canadian Neurocritical Care Society
- The Canadian Neuromuscular Group
- The Consortium of Canadian Centres for Clinical Cognitive Research

abbvie



Impacting millions of Canadians

Migraine is a neurological disease with recurring attacks that causes pain and other disabling symptoms. However, migraine is treatable.

We are advancing science that enables healthcare providers to care for people impacted across the spectrum of migraine.

Empowering people in their pursuit of migraine freedom takes all of us.

@abbviecanada



People. Passion. Possibilities.



2021 Henry Dunn — CACN Lifetime Achievement Award

2021 recipient Dr. Peter Humphreys

Dr. Peter Humphreys is one of the most respected pediatric neurologists in Canada. His professionalism, humility, dedication to teaching, and compassion for his patients make him an exemplary role model for all pediatric neurologists.

Dr. Humphreys graduated from medical school at McGill University in 1966, receiving the Holmes Gold Medal for Excellence. He trained in Paediatrics at Boston Children's Hospital, Harvard University and St Mary's Hospital in London, England. He completed his Neurology training at the Montreal Neurological Institute, McGill University in 1973 before joining the Montreal Children's Hospital as staff from 1973-1979. He then founded the Division of Neurology at the Children's Hospital of Eastern Ontario (CHEO) in 1979 as the sole neurologist and one of the founding members of CHEO.

The numerous neurologists he has trained, and continues to train post-retirement, will attest to his clinical acumen, his impressive knowledge of neuroanatomy and his ability to impart this knowledge to medical students, residents and colleagues in a

supportive environment. He was the perfect example of a professor when he conducted bedside neurology "Professor Rounds". His dedication to teaching is reinforced by the publication of his textbook, *The Integrated Nervous System: A Systematic Diagnostic Approach*, now in its second edition. His lifelong learning philosophy lives on through the annual Peter Humphreys Neurosciences Day at CHEO and the annual Peter Humphreys summer studentship award through the CHEO Research Institute.

Clinically, Dr. Humphreys truly believed in family and patient-centred care and delivered care in a thoughtful and professional manner. His passion for clinical excellence and the recognition of an unmet need led to the establishment of the Rett Syndrome clinic at CHEO, seeing patients from childhood to adulthood. This has led to multiple contributions to the Rett Syndrome world from both an advocacy and research perspective. As recognition of his work, he received the Award of Merit from the Ontario Rett's Syndrome Association in 2010.

Teaching and clinical excellence aside, Peter's love for research was evident by the numerous clinical and basic science publications in the fields of Rett Syndrome and cortical malformations. Most importantly, one cannot forget his role as both a loving and supportive husband and father to his three children.

Dr. Humphreys has been a mentor and role model to all who have crossed his path. **We are proud to honor him this year with the 2021 CACN Henry Dunn – Lifetime Achievement Award.**



CNSF 2020 and 2021 Society Prize Winners

Congratulations to our Society Prize Winners from 2020 and 2021.

With the cancellation of the 2020 Congress in Banff, and the 2021 Congress in Toronto, we have missed the presentations of these prize-winning papers.

The abstracts from our 2020 and 2021 prize winners, and all other CNSF accepted abstracts for the 2021 Congress, are now published within the CJNS Abstract Supplement Volume 48 – Supplement S3, available on the CJNS page in Cambridge Core

cnsf.org/congress/call-for-science/call-for-society-prizes

2020 Society Prize Winners

CNS – André Barbeau Prize

David Pellerin

A Novel Recessive TNNT1 Congenital Core-Rod Myopathy in French Canadians

CNS – Francis McNaughton Prize

Houssein Salem Abdou

Identification of predictors of response to Erenumab in episodic and chronic migraine in a cohort of patients: a preliminary analysis

CNSS – K.G. McKenzie Basic Neuroscience Research Prize

Albert Isaacs

Activated gene pathways in post-infectious hydrocephalus (PIH): Proteogenomics and PIH expressome

CNSS – K.G. McKenzie Clinical Neuroscience Research Prize

Mark MacLean

Does gender equality exist in the surgical management of degenerative lumbar disease?

CSCN – Herbert Jasper Prize

Ana Suller Marti

Vagus Nerve Stimulation in patients with therapy resistant generalized epilepsy

CACN – President's Prize

Aris Hadjinicolaou

Nutrition in the first two weeks of life, neonatal brain growth and cognitive outcomes in children born very preterm

2020 Supplementary Society Prize Awards

CNS – Encephalitis Foundation Prize

Adrian Budhram

Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis

CNSS – K.G. McKenzie – Basic Neuroscience Research – 2nd Place

Michelle Kameda-Smith

Musashi-1 is a master regulator of aberrant translation in Group 3 medulloblastoma.

CNSS – K.G. McKenzie – Clinical Neuroscience Research – 2nd Place

Jonathon Chainey

Action-related fixation in microsuturing, a new gaze behaviour metric to differentiate the level of expertise.

CNSF 2020 and 2021 Society Prize Winners (continued)

2021 Society Prize Winners

CNS – André Barbeau Prize

Vincent Picher-Martell

Changes in Leptin, CCL16 and sTNF-RII as a distinctive plasma immune profile in patients with fast progressing ALS

CNS – Francis McNaughton Prize

Aravind Ganesh

Changes in ischemic stroke presentations and associated workflow during the first wave of the COVID-19 pandemic: A population study

CNSS – K.G. McKenzie Basic Neuroscience Research Prize

Pasarikovski

Examining Aneurysmal Healing After Flow Diversion Treatment Using Endovascular Optical Coherence Tomography

CNSS – K.G. McKenzie Clinical Neuroscience Research Prize

Nicholas Sader

Can Quantitative Susceptibility Mapping Help Diagnose and Predict Recovery of Concussion in Children?

CSCN – Herbert Jasper Prize

Emile Lemoine

Entropy on routine EEG: an interictal marker of seizure frequency?

CACN – President's Prize

Djordja Djordjevic

Improving Triaging of EEG Referrals for rule out Infantile Spasms (ITERIS)

2021 Supplementary Society Prize Awards

CNS – Encephalitis Foundation Prize

Julien Hébert

CSF Findings in Early Active Autoimmune Encephalitis

CNS – Francis McNaughton Prize

Cathy Meng Fei Li

Clinical application of T1-w/T2-w ratio images for in vivo comparisons of myelin content in patients with trigeminal neuralgia

CNSS – K.G. McKenzie – Basic Neuroscience Research – 2nd Place

Mathew Voisin

Epigenetic drivers of malignant transformation in diffuse gliomas

CNSS – K.G. McKenzie – Clinical Neuroscience Research – 2nd Place

Benjamin Davidson

Focused Ultrasound Capsulotomy for Refractory Psychiatric Illness

Congratulations

The Canadian Journal of Neurological Sciences

The **CJNS Journal** is owned by the CNSF member societies and features many articles submitted by your colleagues and fellow CNSF members.

Our Editor-in-Chief, Dr Robert Chen, dedicates numerous hours towards the science, the professionalism and the improvements of our Journal publication. He has built a strong Editorial Board and Associate Editors team and we thank them all for their time and dedication.

The CJNS is hosted on Cambridge Core, the new academic platform from Cambridge University Press. Cambridge Core was developed specifically with researchers' needs in mind and was shortlisted for the 'Best publisher user experience award' in November 2019 from OpenAthens. They were impressed with the 'intuitive experience' of using Cambridge Core, which features: design for mobile devices, tailored journal pages, multimedia and graphical abstracts, metrics and digital innovations, tools and services.

CNSF members currently receive full access by logging in as a member on the CNSF website using your CNSF member ID# and your last name as username and password.

The CJNS Journal has been publishing peer reviewed, scientific articles since 1974 and these are all available for viewing online. Check out the multiple features including "Magazine View".

We also publish "Accepted Manuscripts", which helps you get your research out faster. Newly accepted manuscripts are published within a few days of acceptance under "Accepted manuscript". This is a PDF file of the accepted version of the manuscript. This greatly decreases the time from acceptance to publication and "Accepted Manuscripts" are citable.

The CJNS page continues to feature a direct, free access banner link to the Coronavirus Collection of articles on Cambridge.



Dr Robert Chen

Editor-in-Chief:

Robert Chen

Associate Editors:

- Robert Hammond
- Philippe Huot
- Mahendranath Moharir
- Tejas Sankar
- Jeanne Teitelbaum
- Manas Sharma
- Richard Wennberg

Cambridge Core



CJNS Distinguished Reviewer of the Year 2020

David M. Pelz, MD, FRCPC

The Canadian Journal of Neurological Sciences (CJNS) sincerely appreciates the consistent and numerous high quality manuscript reviews that **Dr Pelz** has provided for the CJNS Journal. This award is based on review statistics from 2019.

Dr. Pelz is an Emeritus Professor in the Departments of Medical Imaging, and Clinical Neurological Sciences at the Schulich School of Medicine and Dentistry, Western University and a Consultant Neuroradiologist at the London Health Sciences Centre, London, Ontario. He has practiced diagnostic and interventional neuroradiology at University Hospital since 1983 with a particular interest in cerebrovascular disease.



Dr. David M. Pelz

A native of Toronto, Ontario, he received his undergraduate and medical education at the University of Western, Ontario. Initially undifferentiated during his radiology residency at Western, he came under the spell of Drs. Fernando Vinuela, Allan Fox, Charles Drake, Henry Barnett and the pioneering neuroscientists in London and his career path was launched.

He still enjoys watching his younger colleagues mastering new interventional techniques and devices, reporting clinical imaging, teaching residents and fellows, and contributing to academic neuroradiology whenever opportunities arise.

Thank you Dr. David Pelz. We appreciate your dedication and support of our CJNS Journal.



Presented in October 2021



NEURO CAREERS

- ▶ Looking for a new career opportunity?
- ▶ Looking to advertise a position at your center?

Check out Neuro Careers!

Neuro Careers is an online classified advertising resource on the CNSF website and linked on the CJNS page in Cambridge Core. Direct links to classified ads are also included in the CNSF members' newsletter, the Neuro|News.

Classified ads are posted online for 2 months, for less than \$500. They open as a full page PDF complete with color, graphics and company logos.

Neuro Careers is a great way to advertise job opportunities and fellowships to Neurologists, Neurosurgeons, Pediatric Neurologists, Neurophysiologists, Neuroradiologists and related health care professionals.

To find out more, contact Donna at donna-irvin@cnsf.org.

www.cnsf.org/neuro-careers



Kesimpta[®] ofatumumab

NOW AVAILABLE

POWER TO TREAT ACTIVE RRMS

defined by clinical and imaging features¹

KESIMPTA[®] (ofatumumab injection) is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

**CHOOSE KESIMPTA[®] FOR YOUR
ADULT PATIENTS WITH ACTIVE RRMS.**

FLEXIBILITY OF SELF-ADMINISTERED INJECTIONS¹

- The first injection should be performed under the guidance of an experienced health professional.
- Self-administered subcutaneous injections for trained patients*
- The initial dose is 20 mg SC at weeks 0, 1 and 2, with subsequent monthly dosing of 20 mg SC at week 4.

Consult the KESIMPTA[®] Product Monograph for complete dosing considerations, including assessments before every injection and premedication.



Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval (Quebec) H9S 1A9
www.novartis.ca
Tel: 514-631-6775 Fax: 514-631-1867
Medical Information Tel: 1-800-363-8883

© 2021 Novartis Pharmaceuticals Canada Inc.
All rights reserved.
© Kesimpta is a registered trademark.
March/2021-106672E

Please consult the Product Monograph at www.novartis.ca/kesimptamonograph for important information related to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883 or by email at medinfo.canada@novartis.com.

References: 1. KESIMPTA[®] product monograph. Novartis. January 22, 2021.

SC = subcutaneous

* Administration should be performed by an individual who has been trained to administer the product.



CNSF Committees

Membership Committee

The issue of expanding membership numbers has never been as important as it is today. Every CNSF Society has expressed that this is a high priority objective. Membership retention and growth is vital to the continued success and stability of each of our Societies and the increased numbers will result in higher revenues as well as increased interest and participation by registered delegates at the Congress. This makes us stronger and more relevant as individual Societies and as a Canadian Federation.

The CNSF membership committee is chaired by Jeanne Teitelbaum, and every CNSF society has representation on this committee.

We are reviewing current membership policies and addressing the primary goals of the Membership Committee to:

- Increase the number of full active members in each Society.
- Increase the number of resident members in each Society.
- Expand the number of Societies to include related Neuroscience organizations whose membership is primarily Neurologists.
- Open membership to new types of members (nurses, anesthetists, intensivists, pathologists etc).
- Simplify the membership categories, review the costs of membership and potentially amalgamate certain categories.

Note: the biggest and most important issue that we need to address is how to increase our membership in each of the Society's Full/Active category. We need to build a strong organization whose membership is PRIMARILY neurologists, neurosurgeons and neuroradiologists.

May I help you?



Available year round to assist with questions about your Society, your Membership or CNSF services.

donna-irvin@cnsf.org • 403-229-9544 ext 103

Advocacy – NHCC

Advocacy is an important part of the CNSF mission to support the neuroscience professions in Canada. The work of CNSF members and CNSF Member Societies is essential to the wellbeing of individuals affected by diseases, disorders and injuries of the nervous system, therefore we must advocate with a strong and effective voice to support this work.

In an effort to Advocate Nationally, in the most effective manner, the CNSF joined Neurological Health Charities of Canada (NHCC). The NHCC share our objectives, and have formed a strong coalition in order to serve as one voice with a stronger sense of community and influence for positive change across Canada. For more information and to see the work of Neurological Health Charities Canada (NHCC) visit mybrainmatters.ca.

Each society of the CNSF has representation on an affiliated International society with a reach far beyond our local representation. International societies include organizations from all over the world and therefore the Advocacy efforts managed within these organizations have been extremely helpful in promoting public awareness and generating advocacy throughout the globe.

The CNSF partners with Affiliate and Associate societies, with a goal to increase the awareness of neurological conditions and influence public policy decisions.

Learn More about the Canadian Neurological Sciences Federation Advocacy cnsf.org/about-cnsf/advocacy

Clinical Practice Guidelines Committee

The goals of the Clinical Practice Guidelines Committee are to:

1. Encourage the development, dissemination and implementation of clinical practice guidelines by our Member and Affiliate Societies, and other Canadian groups that would be of benefit to Canadian neuroscientists.
2. Establish a framework and processes for the promotion and endorsement of clinical practice guidelines so that current evidence-based guidelines meet the needs of, and can be communicated effectively to, the membership of the CNSF.
3. Evaluate and adopt for use by the CNSF membership, with appropriate context-specific provisions, Clinical Practice Guidelines developed outside Canada, particularly in the United States and Europe.

Learn More about the CNSF Clinical Practice Guidelines or submit CPGs for Endorsement:

cnsf.org/education/clinical-practice-guidelines.



ZOLGENSMA[®] is now available in Canada

Novartis Pharmaceuticals Canada Inc.
Dorval, Quebec H9S 1A9
www.novartis.ca
Phone: (514) 631-6775 | Fax: (514) 631-1867
Medical Information Phone: 1-800-363-8883

© 2021, Novartis Pharmaceuticals Canada Inc. All rights reserved.
ZOLGENSMA is a registered trademark.

August/2021 – 148158E



MEMBER OF
INNOVATIVE MEDICINES CANADA

 **zolgensma[®]**
(onasemnogene
abeparvovec)

Welcome CSC

The Canadian Neurological Sciences Federation (CNSF) is pleased to announce that the Canadian Stroke Consortium (CSC) has joined the CNSF as a 6th Society. <https://cnsf.org/>

The CNSF looks forward to the CSC being an integral part of our Federation of national specialty Societies and expanding the scope of the CNSF in providing services to the neuroscience community.

Similarly, the CSC is proud to be a contributing Society to the CNSF and to be providing additional services to its members.

Michael Hill, CNSF President

and

Andrew Demchuk, CSC Chair



Check out the new CNSF Website cnsf.org


- Quick access to Webinars, Neuro Careers, CJNS Journal Access, Congress and the latest News
- Keep up with society initiatives and highlights by visiting your Society page
- Visit the new Advocacy Hub and Neuro Surveys pages For Members

**We value our members' input and support.
Thank you!**

cnsf.org



MOVAPO[®] DEMONSTRATED RAPID TREATMENT OF “OFF” EPISODES IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE^{1*}



Statistically significant improvement in UPDRS Motor scores (change from baseline) at 20 minutes with Movapo[®] vs. placebo ($p < 0.0001$).¹

Movapo[®] is indicated for the acute, intermittent treatment of hypomobility, “OFF” episodes (“end-of-dose wearing off” and unpredictable “ON OFF” episodes) in patients with advanced Parkinson’s disease.¹

Clinical Use:

- Movapo[®] is a subcutaneous injection, given as an adjunct to oral medications, and must not be administered intravenously.
- Initiate treatment with use of a concomitant antiemetic, in a clinical setting where blood pressure and pulse can be closely monitored.
- Extra caution in patients > 65 years due to potential age-related comorbidities and increased frequency of certain adverse events.
- Not recommended in patients < 18 years of age.

Contraindications:

- Using concomitant drugs of the 5HT₃ antagonist class, including antiemetics in this class
- Using concomitant antihypertensive medications or vasodilators
- In patients with severe hepatic or renal impairment

Most Serious Warnings and Precautions:

Sudden Onset of Sleep: Sudden onset of sleep has occurred without warning signs, in patients on Movapo[®] and other dopamine agents, during activities of daily living including driving a motor vehicle. These events are **not** limited to initiation of therapy and patients should not drive or engage in activities where impaired alertness could put themselves and others at risk of serious injury or death. If drowsiness or sudden onset of sleep occurs, patients should immediately contact their physician.

Other Relevant Warnings and Precautions:

- Increased risk of falling
- Patients should not consume alcohol
- May cause postural/orthostatic hypotension
- Risk of syncope in patients with a history of postural/orthostatic hypotension, syncope, and severe cardiovascular disease
- Patients may experience coronary events or exacerbation of coronary and cerebral ischemia

- Possible QTc prolongation and potential proarrhythmic effects
- Severe nausea and vomiting at recommended doses; use with a concomitant antiemetic
- In patients with a sulfite sensitivity, may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes
- May cause dyskinesia or exacerbate pre-existing dyskinesia
- Rapid dose reduction, withdrawal, or antiparkinsonian therapy changes may cause symptoms resembling neuroleptic malignant syndrome
- May cause somnolence
- Increased susceptibility to retinal atrophy/degeneration in human albinos compared to normally pigmented people cannot be excluded
- Unknown whether non-ergot derived dopamine agonists can cause fibrotic complications
- Not recommended in patients with a major psychotic disorder
- Patients may experience hallucinations, new or worsening mental status, and behavioral changes
- Possible impulse control disorders including compulsive behaviours/intense urges
- May cause prolonged painful erections
- Monitor for melanomas
- Risk of injection site reactions
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Breast-feeding is not recommended
- Mild and moderate hepatic and renal impairment

For more information:

Please consult the Product Monograph at http://www.paladin-labs.com/our_products/Movapo_en.pdf for important information relating to adverse reactions, drug interactions, and dosing information that have not been discussed in this piece.

The Product Monograph is also available by calling us at 1-888-867-7426.

PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale.

* Randomized, double-blind trial in 62 patients using Movapo[®] for at least 3 months. Hypomobile patients (on usual PD meds) were randomized to (1) Movapo[®] at usual maintenance dose (2–10 mg), (2) placebo at matching Movapo[®] volume, (3) Movapo[®] at usual dose + 2 mg, (4) placebo at matching Movapo[®] volume + 2 mg. The recommended starting dose of Movapo[®] is 0.2 mL (2 mg), titrated on the basis of effectiveness and tolerance, up to a maximum dose of 0.6 mL (6 mg). Individual doses above 0.6 mL are not recommended. Total daily dose should not exceed 2 mL (20 mg).

† Part III of the UPDRS was the primary outcome assessment measure; it contains 14 items designed to assess the severity of the cardinal motor findings in patients with Parkinson’s Disease.

‡ UPDRS Motor Scores: 40.6 (placebo) and 42.0 (Movapo[®]) at baseline, and -7.4 and -24.2 mean change from baseline at 20 minutes ($p < 0.0001$).

Reference: 1. Movapo[®] Product Monograph. Paladin Labs Inc. November 21, 2016.



Movapo[®] is a registered trademark of Britannia Pharmaceuticals Limited.
© 2021 Paladin Labs Inc., St-Laurent, QC
1-888-867-7426. www.paladin-labs.com

MOVAPO[®]
apomorphine hydrochloride injection

Continuing Professional Development

The CNSF is committed to providing relevant Continuing Professional Development (CPD) opportunities for our members.

We sincerely thank the Professional Development Committee (PDC) and Scientific Program Committee (SPC) members for the time spent working collaboratively throughout the past two tumultuous years. Even though the 2020 and the 2021 Congress were cancelled due to the ongoing pandemic, there was a lot of work and preparation that occurred in advance of these cancellations. We hope to utilize much of this work and bring forward most of these sessions to our 2022 [Congress](#) Program.

Each society of the CNSF has representation on these committees to ensure that the learning needs of each specialty is reflected within our CPD programs.

Congress Planning Committee members

- Cian O'Kelly, CNSF PDC Chair (CNSS member)
- David Mikulis, CNSF PDC Vice Chair (CSNR member)
- Joe Megyesi, CNSF SPC Chair (CNSS member)
- Gerald Pfeffer, CNSF SPC Vice Chair (CNS member)
- Alexandre Henri-Bhargava, CNS PDC
- Shannon Venance, CNS PDC
- Draga Jichici, CNS SPC
- Maryam Nouri, CACN PDC
- Helly Goez, CACN SPC
- Hugh McMillan, CACN SPC
- Michelle Mezei, CSCN SPC
- Kristen Ikeda, CSCN SPC
- Seyed Mirsattari, CSCN PDC
- Laila Alshafai, CSNR SPC
- Jai Shankar, CSNR SPC
- Kirsten Sjonnesen, CACN Resident Rep
- Lindsey Logan, CACN Jr Resident Rep
- Michelle Kameda-Smith, CNSS Resident Rep
- Michael Rizzuto, CNSS Jr Resident Rep
- Jeremiah Hadwen, CNS Resident Rep
- Shane Arsenault, CNS Resident Rep
- Hayley Thornton, CNS Jr Resident Rep
- Daniel Duggan, CSNR Resident Rep
- Michael Hill, CNSF President (CNS member)
- Kristine Chapman, CNSF Vice President (CSCN member)
- Tejas Sankar, CNSF Vice President (CNSS member)
- Cecil Hahn, CNSF Vice President (CACN member)
- Karel Terbrugge, CNSF Vice President (CSNR member)
- Christian Stapf, CNSF Vice President (CSC member)
- Dan Morin, CNSF CEO

Informed by feedback from Congress attendees, the CNSF Membership Survey and other related information and feedback, the PDC and SPC met on a regular basis to develop the program that we hope will see its way into reality in June 2022 in Montreal.

Thank you all.

Virtual Exhibit Hall

The CNSF online Virtual Exhibit Hall (VEH) provides the opportunity for the current year of CNSF Sponsors and Exhibitors to showcase their company and provide links to their websites and contact information to our members.

The CNSF is proud to showcase these CNSF Supporters and their contributions to the Canadian Neurological community.

veh.cnsf.org





Roche Canada prides itself on its mission of *Doing now what patients need next*

We know that in order to **advance science**; in order to **mobilize communities**; in order to make a **meaningful impact** on society, we need to be **entrepreneurial** in our spirit and **bold** in our thinking.

We do this today in hopes of building a better tomorrow.

We are Roche.



www.rochecanada.com

© Copyright 2021, Hoffmann-La Roche Limited



Hoffmann-La Roche Limited
Mississauga, ON L5N 5M8



We asked two CNSF members for their views on work and life...

Hugh McMillan

Q. Was there a defining moment that led you to choose the neurosciences as your career, and why?

A. During my first night of call as a pediatric resident at McMaster Children's Hospital, I cared for an infant who had just been transferred from the NICU to the inpatient ward. He was born after a congenital CMV infection causing severe brain malformation and epilepsy. I was called for a code blue when he aspirated liquid anti-convulsant medication. I remember learning two things that evening and in months that followed. First, I had no desire to become a critical care physician. Secondly, while we do not have control over what disease our patients may develop in their lifetimes, we have a tremendous control over how bad news is shared. Sensitivity and compassion can allow patients and their families to move past that terrible moment of disclosure and continue to move forward with their lives rather than being forever stuck in anger, resentment and other negative emotions. I have always viewed neurosciences as a complex and challenging area of medicine not only to ensure that the correct diagnosis is made but to ensure that it is communicated effectively and compassionately to patients and their families.

Q. What was the greatest piece of advice you have received?

A. One of my mentors once taught me that the fastest way to stop critical thinking is to give someone a diagnosis. I learned how important it is never to give a diagnosis until one is certain it is correct, and when seeing a patient for the first time to review and understand their initial symptoms and investigations to ensure that you agree with a diagnosis that may have previously been given.

Q. What do you do when you have down time?

A. Hiking – either a day hike on a nearby trail or a multi-day hiking trip. It's a great way to be physically active with my partner, our teenaged son and our two dogs. Time seems to slow down whenever I step onto a forest trail or a mountain path. And I'm always amazed at how much more simple life seems to become when smart phones are left behind and the internet connection has been cut. I feel very fortunately to have so many beautiful places to explore.

Q. What do you think of when you hear the words brain health?

A. I see brain health as being somewhat reductionist. While it is critical to seek a personal balance between mental stimulation and rest, it is after all only one part of our overall health along with psychological, emotional and physical well-being.

Q. What is your favorite book and why?

A. *The Immortal Life of Henrietta Lacks* by Rebecca Skloot. During my undergraduate and graduate school training in Biology, I remember reading about and studying HeLa cells. I am embarrassed to admit that not once did I ever think about where (or from whom) these cells came from. Reading about the struggles of Henrietta, her family and so many others like her, really crystalized how important it is for clinical research to be transparent and ensure that patients are fully informed and consent for treatments that are offered and/or blood, body tissues and/or genetic material that may be studied.

Q. Which technology could you do without?

A. My iPhone with whom I have a love-hate relationship.

Q. What one thing could everyone do to stay brain healthy?

A. The basis of neuroplasticity is that synaptic connections used frequently will develop stronger connections and fire more easily. To this end, be kind to oneself and be kind to others. Make the positive neural networks stronger and allow those that no longer benefit you to be pruned.

Q. How has your career in medicine created value in your life?

A. Life is beautiful, yet fragile. My patients remind me every day of how important it is to fully embrace life and to live joyfully in the present..

Q. What advice would you give to someone aspiring to be successful?

A. I like the Banksy's quote; "if you get tired, learn to rest not to quit". The focus of hard work and excellence must be balanced with being gentle with oneself.



Mitsubishi Tanabe Pharma Canada: Supporting ALS Management and Awareness

ALS remains one of the most challenging diseases to manage. But there is hope—and Mitsubishi Tanabe Pharma Canada is committed to fueling that hope through our partnerships with the ALS Society of Canada. In the last year, we have supported:



Revolution Ride



Plane Pull to
End ALS



Mitsubishi Tanabe Pharma
Canada Fellowship



ALS Research
Forum



ALS Awareness
Month

Mitsubishi Tanabe Pharma Canada is also committed to providing ALS education resources to healthcare providers through ALSPathways.ca

In Canada, the road to ALS diagnosis is long and can take an average of 21 months.¹ ALS Pathways is a website designed to help close this diagnostic gap by providing information and free resources developed by ALS experts to the neurology community. Visit now to access:



Information on ALS
diagnosis, assessment,
& management



Patient
Education
Resources



Podcasts
(featuring ALS
experts)




Videos
(featuring ALS
experts)



ALS
Diagnosis Tool

Visit www.alspathways.ca/hcp to learn more!



ALS, amyotrophic lateral sclerosis.

Reference:

1. Hodgkinson VL, et al. Provincial differences in the diagnosis and care of amyotrophic lateral sclerosis. *Can J Neurol Sci.* 2018;45(6):652-659.

The corporate symbol of Mitsubishi Tanabe Pharma Canada is a registered trademark of Mitsubishi Tanabe Pharma Corporation. ALS Pathways is a trademark of Mitsubishi Tanabe Pharma Canada, Inc. For Canadian audiences only. Mitsubishi Tanabe Pharma Canada, Inc. <https://www.mt-pharma-ca.com>

© 2021 Mitsubishi Tanabe Pharma Canada, Inc. All rights reserved. Canada Only. CNP-MTPCA-CA-0018 08/21

We asked two CNSF members for their views on work and life...

Seyed Mirsattari

Q. Was there a defining moment that led you to choose the neurosciences as your career, and why?

A. In grade 9, I unexpectedly lost my young and otherwise very healthy uncle to brain tumor. He left behind 3 young children, the third of whom was born after his passing. This tragic event motivated me to understand diseases that affect the brain and search for remedies to human sufferings..

Q. What was the greatest piece of advice you have received?

A. Early in my training, Brian Schmidt, my residency program director, advised me to write my American exams at the same time as I was doing my Canadian equivalents. He passed Quebec provincial exam in Neurology along with French Language test as he completed his neurology residency in McGill University. I took his advice to heart and obtained all my USMLE exams followed by the American Board examination in Psychiatry and Neurology even though I had no immediate plans to practice medicine in the USA. He taught me the value of being prepared for the unexpected turns of events in life. I have broadened its implications in my life and have passed this advice to my trainees: Do not miss the opportunity to get something done when you are most suited to do it.

Q. What do you do when you have down time?

A. Long distance cycling in the quiet country roads is my favourite activity during my down time. When I can, I like to get away to our cottage in Pelee Island, which is my ultimate get away from the hustles and bustles of modern life in pursuit of serenity, yard work, swimming, good sleep, and more cycling.

Q. What do you think of when you hear the words brain health?

A. To me, brain health means maintaining a sharp and active mind as long as we live. The best way to achieve this is by physical exercise, reading, satisfying career, and engaging in a meaningful social life. Resourcefulness is the ultimate way to maintain a healthy brain; believing that our brain has the solutions. We just need to search for them! Start small. Stay physically and mentally active. Use stairs instead of elevators at work. Bike instead of ride to work. Take healthy meals to work and cutback reliance on fast food. Sleep and rest well. Let the younger minds challenge us.

Q. What is your favorite book and why?

A. My favourite book is *The Brothers Kramazov* by Fyodor Dostoevsky. Reading it as a neurologist and epileptologist, I had a different perspective than its main plot: patricide. The depiction of epilepsy, epileptic seizures [non-epileptic seizures], the perceived role of doctors in the society through the author's lenses was very informative. Dostoevsky lived a turmoil life and allegedly suffered from epilepsy. His dislikes for



physicians whom he portrayed as well-dressed men prescribing pills and getting paid well show up throughout his writings. When I discuss treatment options with my patients, his fear of being prescribed more pills when he sees his doctors resonates in the back of my mind and I make sure to address my patients' overall health. I often cite famous people with epilepsy including Dostoevsky as an accomplished novelist to my patients with new diagnosis of epilepsy. It is my goal to convey to my patients that they should not be defined by their illness and live their lives to their full potentials..

Q. Which technology could you do without?

A. I have not missed out on life without ever having a twitter account, Facebook, Instagram, or Snapchat! This is an added distraction that brings no meaning to our lives or careers! It does more harm than good. The tense relationship between Canada and the Kingdom of Saudi Arabia that caused so much unintended immediate adverse consequences in medical care in Canada started with twitting! Choose a meaningful dialogue over hasty messages on social media to get things done!

Q. What one thing could everyone do to stay brain healthy?

A. Get enough sleep! We are chronically sleep deprived because of our life styles. Restful sleep can restore brain from fatigue. We all need it!

Q. How has your career in medicine created value in your life?

A. Practice of medicine is a unique privilege to connect to people. It is priceless! It is a truly humbling experience to see resilience in people struggling with severe chronic ailments. I stop complaining about trivial inconveniences in life when my patients are facing life and death with grace. They help me to stay humble and put it into perspective. .

Q. What advice would you give to someone aspiring to be successful?

A. Never give up! Learn from your failures. Set your own internal measures of success and ignore the outside noise. Set the pace and never look back. You will get there! I lived alone in a refugee camp for 18 months. You can do it!

SANOFI GENZYME, A COMMITTED LEADER IN POMPE DISEASE AND PROUD SPONSOR OF CNSF

Contact your local Sanofi Genzyme team to see how we can help.



Reference: 1. American Association of Neuromuscular & Electrodiagnostic Medicine. *Muscle Nerve* 2009;40(1):149–60.

SANOFI GENZYME 

IMAT-CA-2101079E

2021 Major Supporters

The cancellation of CNSF's 2021 Congress was, to say the least, disappointing. Our members, delegates, chairs and speakers supported our decision. So too, did our sponsors who had committed significant human and financial resources to the Congress.

We have discussed the situation with all our major supporters and, in the case of our Lunch 'n Learn and Dinner Session sponsors, have attempted to transition these sessions into webinars for the fall of 2021 and early 2022. Those confirmed webinars are indicated by *** below.

We felt it appropriate to include all of our supporters' intentions for 2021's Congress below.

Thank you to:

DIAMOND

- ▶ **Novartis Pharmaceuticals Canada Inc*****
for the support of the 2021 CNSF prepOSCE Program, two fall 2020 Webinars, a 2021 Webinar, two 2021 Congress Lunch 'n Learns, Grand Rounds support, 2 Exhibit Booths and Neuro|News advertising. Webinar on SMA planned.
- ▶ **Hoffmann-La Roche**
for the support of the 2021 CNSF prepOSCE Program, two fall 2020 Webinars, Grand Plenary support, an Exhibit Booth and Neuro|News advertising.

GOLD

- ▶ **Alexion Pharma Canada*****
for the support of a fall 2020 Webinar, a 2021 Lunch 'n Learn, an Exhibit booth and Lanyard sponsorship.
- ▶ **Anylam Pharmaceuticals*****
for the support of a fall 2020 Webinar, a 2021 Lunch 'n Learn and 3 Exhibit booths.
- ▶ **Amylyx*****
for the support of a 2021 Lunch 'n Learn, 2 booths, Neuro|News and VEH advertising.
- ▶ **Medtronic Canada*****
for the support of 3 fall 2020 Webinars, a 2021 Lunch 'n Learn and 3 Exhibit booths.
- ▶ **Mitsubishi Tanabe Pharma Canada*****
for the support of a 2020 Webinar, a 2021 Lunch 'n Learn, an Exhibit booth, Neuro|News advertising and on site Post Card distribution

SILVER

- ▶ **Grifols**
for the general support of the CNSF, the support of the Neuromuscular Clinical Case Study and a Fellowship Grant to CSCN for 2020/2021.
- ▶ **Integra Canada ULC*****
for the support of a 2021 Lunch 'n Learn and 2 Exhibit booths.
- ▶ **Eli Lilly Canada**
for 2 booths and 2 ads in Neuro|News.
- ▶ **MD Financial Management**
for sponsorship of the 2021 Exhibitors' Reception and the Residents' and Faculty Social, an Exhibit booth, Neuro|News advertising, and the purchase of advertising in each issue of the Journal.
- ▶ **Paladin Labs Inc.**
for an Exhibit booth, Neuro|News advertising and sponsorship of the Course Notes website and 2021 Congress App.
- ▶ **Sanofi Genzyme**
for the support of a 2021 Lunch 'n Learn and 2 Exhibit booths.

SUPPORTER

- ▶ **Allergan, an AbbVie Company**
for a 2021 Exhibit booth, Neuro|News advertising and on site Post Card distribution.

Thank you to our 2021 Major Supporters

DIAMOND



GOLD



Mitsubishi Tanabe Pharma Canada

SILVER



MD Financial
Management



SANOFI GENZYME 

SUPPORTER

